FIELD: biotechnology.
SUBSTANCE: invention refers to a pharmaceutical composition for treating endothelial dysfunction and/or atherosclerotic vascular disease. Said composition contains peptides consisting of fragments of proteins Transgelin, Actin and Biglycan. Present invention also relates to use of said composition for treating chronic obliterating arterial diseases of lower limbs (COADLL) and erectile dysfunction in males.
EFFECT: invention provides a pharmaceutical composition with high biological activity in the absence of acute and chronic toxicity, carcinogenic, embryotoxic, mutagenic, immunotoxic and teratogenic properties, as well as local irritant and allergenic action.
6 cl, 2 dwg, 8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING REPRODUCTIVE DISORDERS IN MEN AND USE THEREOF | 2024 |
|
RU2837217C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION IN MEN AND USE THEREOF | 2024 |
|
RU2837354C1 |
| ANTIGENIC PEPTIDES FOR PREVENTION AND TREATMENT OF B-CELL HEMOBLASTOSIS | 2020 |
|
RU2833806C1 |
| BISPECIFIC ANTIBODIES AND THEIR APPLICATIONS | 2022 |
|
RU2821577C2 |
| PEPTIDE USED FOR IMMUNOTHERAPEUTIC AGENTS | 2021 |
|
RU2836172C1 |
| PROPERDIN ANTIBODIES AND PRODUCTION THEREOF | 2021 |
|
RU2830308C1 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORTING SEGMENT | 2018 |
|
RU2841528C2 |
| ISOLATED MODIFIED CAPSID PROTEIN VPI OF ADENO-ASSOCIATED VIRUS SEROTYPE 5 (AAV5), CAPSID AND VECTOR BASED THEREON | 2021 |
|
RU2820088C1 |
| CHIMERIC CYTOKINE RECEPTORS CARRYING PD-1 ECTODOMAIN | 2020 |
|
RU2828214C2 |
| BCMA-SPECIFIC CHIMERIC ANTIGEN RECEPTORS CONTAINING IL-6 SIGNALLING BLOCKER | 2023 |
|
RU2828294C1 |
